U.S. markets closed

VolitionRx Limited (VNRX)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
3.4500+0.0200 (+0.58%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close3.4300
Bid2.9600 x 1800
Ask3.4800 x 800
Day's Range3.4000 - 3.5000
52 Week Range2.8500 - 6.6700
Avg. Volume95,912
Market Cap183.617M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-0.4210
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VNRX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VolitionRX Limited
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to to view presentationsNEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the September 16th conference are now available for on-demand viewing at This virtual event showcased live executive presentations and interactive discussions focused on publicly traded companies in the life sciences

  • GlobeNewswire

    Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th

    Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.comNEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional

  • Zacks Small Cap Research

    VNRX: Revenues from Nu.Q Vet Cancer Screening Test steady from beta test; Silver One expected to generate revenues in late 2021.

    By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT VolitionRx (NYSE:VNRX) is engaged in multiple epigenetic projects based on company’s proprietary Nu.QTM platform that has developed numerous blood-based clinical assays . The beta launch of Nu.Q Vet Cancer Screening Test is currently generating revenue, and management is in active discussions with a ranger of smaller and